VIP (Vasoactive Intestinal Peptide) (Nasal Spray)

VIP acts via VPAC1/VPAC2 receptors, reducing inflammatory cytokines (TNF-α, IL-6), regulating T-regulatory cells, and improving pulmonary function. The intranasal route allows for local action on the nasal mucosa and potential central access via the olfactory nerve.

• Nasal administration — no injection
• Dosing: 50 mcg per spray, 4×/day (Shoemaker protocol)
• Use only after completing steps 1–11 of the Shoemaker protocol
• No reconstitution required — ready-to-use formulation

• VIP is administered intranasally, primarily within the framework of the Shoemaker protocol for CIRS (Chronic Inflammatory Response Syndrome).
• The nasal bioavailability of VIP is not fully documented, but clinical experience supports the use of this route.
• Extremely sensitive peptide — requires strict refrigeration and careful handling.

• Available as a ready-to-use nasal spray from specialized compounding pharmacies.
• Self-compounding a nasal spray is not recommended due to the peptide's sensitivity.
• Typical concentration: 50 mcg per spray.

• Refrigerate (2–8 °C) after opening.
• Use within 14 days.
• Ideally: freeze in aliquots for longer shelf life.

• Use only after completing the Shoemaker protocol (steps 1–11).
• Start with 50 mcg (1 spray/nostril), 4×/day.
• Increase to 100 mcg (2 sprays/nostril) after 2 weeks if well tolerated.
• Cycle: 30 days or as per medical guidance.

• Refrigerate (2–8 °C) — mandatory.
• Protect from light and heat.
• Use within 14 days after opening.

• Use ONLY after completion of the Shoemaker protocol (CIRS).
• May cause hypotension — start with a low dose.
• Extremely sensitive peptide — avoid room temperature.
• Self-compounding instructions are not provided.

Potential Benefits

• Potent anti-inflammatory action (CIRS/mold).
• Improved pulmonary function.
• Neuroprotection and vasodilation.
• Circadian rhythm regulation.
• Non-invasive administration (no injection).

Potential Side Effects

• Hypotension (most common side effect).
• Nasal congestion or irritation.
• Diarrhea at high doses.

1. VIP in CIRS — Shoemaker RC, et al. Vasoactive intestinal polypeptide as a biomarker of CIRS. Neurotoxicol Teratol. 2013;40:35-44.
   Source →
2. VIP Immunology — Delgado M, et al. VIP and PACAP as immunomodulators. Ann N Y Acad Sci. 2003;1070:51-74.
   Source →
3. VIP Nasal Administration — Shoemaker RC, House DE. Sick building syndrome and exposure to water-damaged buildings. Neurotoxicol Teratol. 2006;28(5):573-88.
   Source →